With the prospect of losing a third of its revenue because of patent expiration in 2014, Eli Lilly has bet big on oncology and diabetes drugs. In this video, David Williamson highlights the success so far, and the possible challenges, for Lilly's diabetes drug, dulaglutide. Type 2 diabetes is a big problem, and David says Lilly seems well positioned to benefit from its growing prevalence, although investors need to remember there will be some patent-expiration bumps along the way. Check out the video for more details.
David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
